Alan Meds vs Sesame Care
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alan Meds
Best for budget-conscious shoppersStarting at $99/mo
Sesame Care
Best for Brand-name GLP-1 buyers (Wegovy or Zepbound) who want LillyDirect-grade cash pricing on Zepbound vials/KwikPens or NovoCare-style first-two-month promo pricing on Wegovy without compounding risk, AND who value the ability to browse named providers with displayed prices before booking. Especially well-suited for patients in the 41 states with included lab work, patients with commercial insurance willing to pursue prior authorization for $25/mo medication access, and patients who want a single platform for weight-loss + adjacent specialties (mental health, dermatology, women's health). NOT appropriate for buyers seeking compounded GLP-1s at the $99-$249/mo budget tier (Sesame is brand-name-only for GLP-1s), buyers who require provider credentials curated and vetted by a single medical group rather than an independently-operated marketplace, or buyers in the 9 lab-excluded states unwilling to bear separate lab costs.Starting at $25/mo
Side-by-Side Comparison
| Feature | Alan Meds | Sesame Care |
|---|---|---|
| Overall Score | ✓7.7/10 | 7.5/10 |
| Starting Price | $99/mo | ✓$25/mo |
| Editorial Rating | ✓3.9 ★ /5 | 3.8 ★ /5 |
| Features | 5 features | ✓12 features |
| States Available | ✓46 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | — | — |
| FSA/HSA Accepted | — | ✓ Yes |
| FDA Warnings | None | None |
Pros & Cons
Alan Meds
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
Sesame Care
Pros
- ✓Marketplace transparency — patients pick a specific named provider with displayed price BEFORE booking, unlike most telehealth providers where the prescribing clinician is opaque until after intake
- ✓BBB-accredited AND LegitScript-verified — trust trifecta complete (only LegitScript-verified compounding partner is missing, but Sesame's GLP-1 supply is branded via LillyDirect/NovoCare, not compounded)
- ✓LillyDirect partnership unlocks Zepbound vial and KwikPen cash pricing that matches Lilly's lowest-disclosed direct-to-consumer rates ($299 at lowest dose) — no other WLR-listed provider has this verified partnership
- ✓Wegovy self-pay promo ($199/mo for first two months, lowest dose, new self-pay only) is one of the lowest brand-Wegovy cash prices in the WLR directory through 2026-06-30
- ✓Subscription model is honest about scope — clinical care only, medication billed separately — vs. compounded-GLP-1 providers that bundle the two and obscure the medication's actual cost basis
- ✓Wegovy pill ($149/mo low doses) and Foundayo orforglipron are both stocked — Sesame is one of few providers offering both oral semaglutide AND orforglipron alongside injectables
- ✓Lab work included in subscription for 41 states (excludes AZ/HI/ND/NJ/NY/OK/RI/SD/WY)
- ✓Insurance route ($25/mo possible) is genuinely viable — providers assist with prior authorization paperwork, not just a marketing line
- ✓Cross-vertical platform means established patients can stay in-network for ED, mental health, women's health follow-ups — engagement and retention advantage
- ✓Eligibility criteria disclosed transparently (BMI 30+ or 27+ with comorbidity; standard MTC/MEN2/pancreatitis/Type 1 exclusions for GLP-1)
Cons
- ✗Marketplace model means the prescribing clinician's credentials, malpractice history, and state licensure are the INDIVIDUAL provider's, not Sesame's — quality varies provider to provider in a way that does not apply to single-physician-group competitors
- ✗States_available CANNOT be enumerated at the platform level — depends entirely on which providers in the marketplace are licensed in a given state — left empty per WLR data-discipline rule for marketplace operators
- ✗No pharmacy ownership — Sesame does not operate its own dispensing pharmacy; fulfillment is split between LillyDirect (Zepbound), NovoCare (Wegovy self-pay), and the patient's preferred retail pharmacy depending on the medication and the patient's insurance
- ✗Refund policy is restrictive: full refund only if cancellation occurs at least 3 hours prior to initial visit; no refunds for first month if initial visit occurred; previously-paid months are non-refundable
- ✗Subscription requires commitment — no genuine pay-per-visit option for the weight-loss vertical even though Sesame's broader urgent-care platform is famously per-visit
- ✗Limited-time Wegovy promo ($199/mo) gates on (a) new self-pay patient status, (b) lowest dose strength (0.25mg/0.5mg) only, (c) standard $349/mo applies after month 2 — a structurally honest disclosure but the headline price is the floor, not the average
- ✗Wegovy pill high-dose pricing ($299/mo for 9mg/25mg) is roughly 2x the low-dose price — patients titrating up the oral semaglutide ladder face material month-over-month cost increases
- ✗Zepbound KwikPen high-dose pricing ($699/mo for 10mg-15mg) approaches Lilly's list price — the LillyDirect discount narrows significantly at higher doses
- ✗Lab work excluded in 9 jurisdictions (AZ/HI/ND/NJ/NY/OK/RI/SD/WY) — patients in those states bear lab cost separately on top of the subscription
- ✗No published medical-director name or chief-medical-officer biography on the public site — marketplace by design means no single physician owns clinical governance
- ✗Katalys multi-payout offer ($175/$80/$140) is PENDING approval — affiliate_url is bare sesamecare.com until tracking URL with offer_id and aff_id parameters is issued
- ✗Existing _id 'sesame' record (added 2026-04-07) is a stale 'compounded' stub that mis-classifies Sesame's brand-only GLP-1 model — recommend deprecating that record in a follow-up pass to avoid duplicate surfacing on /compare and /best pages
Our Verdict
Alan Meds edges out Sesame Care with a higher overall score of 7.7/10 and is particularly strong for budget-conscious shoppers. Sesame Care remains a solid alternative, especially if you're looking for Brand-name GLP-1 buyers (Wegovy or Zepbound) who want LillyDirect-grade cash pricing on Zepbound vials/KwikPens or NovoCare-style first-two-month promo pricing on Wegovy without compounding risk, AND who value the ability to browse named providers with displayed prices before booking. Especially well-suited for patients in the 41 states with included lab work, patients with commercial insurance willing to pursue prior authorization for $25/mo medication access, and patients who want a single platform for weight-loss + adjacent specialties (mental health, dermatology, women's health). NOT appropriate for buyers seeking compounded GLP-1s at the $99-$249/mo budget tier (Sesame is brand-name-only for GLP-1s), buyers who require provider credentials curated and vetted by a single medical group rather than an independently-operated marketplace, or buyers in the 9 lab-excluded states unwilling to bear separate lab costs..
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring Alan Meds and Sesame Care head-to-heads in the same category.
- Alan Meds vs CoreAge Rx
- Alan Meds vs TrimRx
- Alan Meds vs Amazon One Medical
- Sesame Care vs NovoCare Pharmacy
- Sesame Care vs Vytora Health
- Sesame Care vs Enhance MD
Or see the full category ranking.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.